Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA

Back

Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer

Author(s): Xiaoyang Li, Jian Zhang, Yuanchao Xie, Yuqi Jiang, Zhang Yingjie and Wenfang Xu

Affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, China.

Keywords: Combined therapy, hematologic malignancies, histone deacetylase inhibitors, monotherapy, panobinostat, solid tumors.

Abstract:

Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 15
ISSUE: 6
Page: [622 - 634]
Pages: 13
DOI: 10.2174/1389450115666140306152642